Scholar Rock: Funding, Investors & Team (Sep 2026)

Scholar Rock is a biopharmaceutical company that specializes in discovering and developing groundbreaking medications for the treatment of severe diseases that involve protein growth factors. By gaining a greater understanding of how these growth factors activate, we have been able to create a unique platform for identifying and developing monoclonal antibodies that specifically target these signaling proteins at the cellular level. This strategy, which focuses on the disease microenvironment, aims to overcome previous challenges associated with inhibiting growth factors for therapeutic purposes. By concentrating on growth factors that have been scientifically proven to be biologically significant, we hope to streamline the development process. Our main product candidate, SRK-015, is a selective inhibitor that targets the activation of the growth factor myostatin in skeletal muscle for the treatment of spinal muscular atrophy (SMA). We anticipate starting Phase 1 clinical trials in the second quarter of 2018. Additionally, leveraging our proprietary platform, we are also working on creating a pipeline of innovative treatment options for other neuromuscular disorders, cancer, fibrosis, and anemia, with the potential to greatly improve the lives of patients suffering from these conditions.

Scholar Rock has raised $385M across 2 rounds on record. The most recent is an undisclosed round of $300M announced in Oct 2024.

Scholar Rock's most recent funding round on record is an undisclosed round of $300M, announced in Oct 2024.

FundedIQ lists Nagesh K Mahanthappa (Founder) at Scholar Rock.

Scholar Rock is based in Cambridge, Massachusetts, United States.

Scholar Rock is in the 101-250 employee band.

Scholar Rock's latest round of $300M is above the $8.0M median round size for Biotechnology companies on FundedIQ across 4,182 tracked companies over the last two years.